Fezolinetant is associated with a hepatic adverse event reporting signal characterized primarily by transaminase elevations rather than clinically overt liver injury.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fezolinetant-shows-hepatic-signal-dominated-lab-2026a1000i98?src=rss
Author :
Publish date : 2026-06-02 06:39:00
Copyright for syndicated content belongs to the linked Source.